HZNP — Horizon Therapeutics Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge Cap

Annual cashflow statement for Horizon Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2018 December 31st	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-74.2	573	390	534	521
Depreciation
Deferred Taxes
Non-Cash Items	202	184	266	310	308
Unusual Items
Purchased R&D
Other Non-Cash Items
Changes in Working Capital	-144	-2.5	-346	-61.7	-12
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Cash from Operating Activities	195	426	556	1,035	1,258
Capital Expenditures	-4.77	-17.9	-170	-76.6	-64
Purchase of Fixed Assets
Other Investing Cash Flow Items	32.4	0	-294	-2,918	-70
Acquisition of Business
Sale of Business
Sale of Fixed Assets
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	27.7	-17.9	-464	-2,994	-134
Financing Cash Flow Items	-14.5	-28.3	-66.5	-166	-137
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-16.6	-290	905	1,470	-348
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	204	118	1,003	-499	773